Runze

Jiangsu Runze Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for cancer and autoimmune diseases. The company specializes in targeting key signaling pathways, with a particular emphasis on the phosphoinositide 3-kinase (PI3K) family. Its lead clinical candidate, RZ-001, is a potent dual inhibitor of PI3K delta and gamma isoforms currently being evaluated in Phase 2 trials for hematologic malignancies such as B-cell lymphoma. Runze Pharmaceutical maintains a robust internal pipeline of early-stage programs, including RZ-518 and RZ-608, aimed at addressing unmet medical needs. The company is supported by prominent Chinese venture capital firms and operates state-of-the-art R&D facilities in the Suzhou Industrial Park.